5-Amino-1MQ SubQ Dosage Per Day: What Research Shows

There is no established or FDA-approved 5-amino-1MQ subQ dosage per day for humans. In rodent studies, 5-amino-1MQ has been given orally at approximately 5 mg/kg daily, but no human trials have defined a safe or effective subcutaneous dose. Any human use is experimental and not recommended by regulatory agencies.

What Is 5-Amino-1MQ?

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It is not a peptide, and it is not approved by the FDA for any human condition. Researchers study it for its effects on fat metabolism and energy expenditure in animals.

The compound is sold online as a research chemical, often in capsules or as a powder for injection. These products are not intended for human consumption. The lack of human clinical trials means no standard dosing exists.

In one notable 2018 study, obese mice given 5-amino-1MQ orally for 10 days lost weight and improved glucose tolerance. The dose was 5 mg/kg per day. No human trial has replicated these results.

5-Amino-1MQ SubQ Dosage: What the Research Shows

Subcutaneous injection of 5-amino-1MQ has not been studied in humans. Animal research has used oral administration, not injections. Therefore, any 5-amino-1mq dosage subcutaneous reported online is based on anecdotal experience, not science.

When people search for a 5-amino-1mq dosage per day, they often encounter forum posts with widely different numbers. Some report 50 mg daily, others 100 mg or more. There is no consistency or safety data behind these figures.

The most commonly discussed 5-amino-1mq subcutaneous injection dosage in online communities is 50 mg once daily. However, this is not a recommendation.

Subcutaneous injection is a common route for peptides, but 5-amino-1MQ is not a peptide. Its small size means it may be absorbed differently. Without pharmacokinetic data, it is impossible to know how much reaches target tissues.

Table 1 compares what is known from research versus anecdotal reports.

Route	Research Setting	Typical Reported Amount	Human Data?
Oral (animal)	Mouse studies	5 mg/kg per day	No
Subcutaneous (anecdotal)	Online forums	50–150 mg per day	No
Oral (human anecdotal)	Online forums	50–100 mg per day	No

Oral vs. Subcutaneous Dosing Compared

Oral and subcutaneous routes are not interchangeable. Oral bioavailability of 5-amino-1MQ in humans is unknown. Subcutaneous injection bypasses digestion, but it also carries risks of infection and tissue damage.

The 5-amino-1mq oral dosage used in mouse studies was 5 mg/kg per day. If you tried to convert that to a human dose, you would need a conversion factor, but such calculations are unreliable. Many researchers also look into other metabolic compounds, but each has its own unknowns.

Oral dosing is easier and avoids needles. However, stomach acid and liver metabolism may destroy or alter 5-amino-1MQ. No one knows the oral bioavailability in humans. Subcutaneous injection might deliver more intact compound, but it also delivers more risk.

Table 2 summarizes practical differences between the two routes.

Factor	Oral	Subcutaneous
Human research	None	None
Convenience	Higher	Lower
Risk of injection issues	None	Infection, pain, nodules
Typical anecdotal dose	50–100 mg/day	50–150 mg/day

How People Calculate or Estimate Doses

Some websites offer a 5-amino-1mq dosage calculator that converts animal doses to human equivalents. These tools use body surface area scaling, but they do not account for differences in metabolism, absorption, or toxicity.

A calculator cannot replace clinical trials. For 5-amino-1MQ, no human trial has established a safe starting dose, a maximum tolerated dose, or a therapeutic window. Using a calculator to guess a subcutaneous dose is risky.

Other compounds like CJC-1295 and ipamorelin have more human data and active forums, but even for those peptides, online advice is not medical advice.

Safety and Legal Considerations

5-Amino-1MQ is not approved by the FDA for human use. Selling it for human consumption is illegal in the United States. Purchasing it for research purposes may be legal, but injecting it into your body is not an approved use.

Potential risks of subcutaneous injection include bacterial infection, abscess, and allergic reaction. The long-term effects of NNMT inhibition in humans are unknown. Some research suggests NNMT inhibition could affect other tissues, but human data are lacking.

In the US, the FDA has not approved 5-amino-1MQ for any indication. It is not a dietary supplement. Importing it for personal use may violate customs regulations.

You should consult a licensed healthcare professional before considering any experimental compound. A doctor can discuss safer, evidence-based options for metabolic health.

Bottom Line

There is no scientifically established 5-amino-1MQ subQ dosage per day. Animal studies used oral dosing, and human data are absent. Anecdotal reports of 50–150 mg subcutaneously are unverified and potentially dangerous.

If you are considering 5-amino-1MQ for weight loss, remember that no human study supports its use. Safer, proven options exist.

If you are researching 5-amino-1MQ, stick to laboratory studies and avoid self-administration. Your health is not worth an experimental guess.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical 5-amino-1MQ subQ dosage per day?

There is no established typical dosage because no human trials have tested subcutaneous 5-amino-1MQ. Anecdotal reports range from 50 mg to 150 mg per day, but these are unverified and not based on clinical evidence.

Is 5-amino-1MQ FDA-approved for human use?

No. 5-Amino-1MQ is not approved by the FDA for any human condition. It is sold as a research chemical only, and using it in humans is experimental and potentially illegal.

Can I use a 5-amino-1MQ dosage calculator to find my dose?

Dosage calculators that convert animal data to human equivalents are not reliable for 5-amino-1MQ. No human safety or efficacy data exist, so any calculated dose is a guess. Consulting a healthcare professional is strongly advised.